The UK distributor of ENTEROSGEL®, in collaboration with the UK's largest healthcare research company (NIHR), has been named a finalist in the prestigious PharmaField Innovation Asad (Team) award for its virtual trial of an irritable bowel syndrome treatment (RELIEVE IBS-D).
This award is presented annually to a team working in the UK pharmaceutical and medical device industry that has demonstrated an exceptional ability to champion new approaches supported by the National Health Service (NHS) during the year. EnteroMed's joint project with NIHR led to rapid recruitment to one of the first fully virtual interventional clinical trials in England.
Virtual trials are remote access trials that use digital technology to enable recruitment to clinical trials without the patient having to visit a recruitment site. This reduces the risk of infection in a pandemic setting and, just as importantly, allows more patients to participate regardless of where they are. This has been a ground-breaking achievement for the NHS.
Professor Yan Yiannakou, Clinical Director of the NIHR Patient Recruitment Centre said: "I am delighted to have been recognized as a finalist for the work we have done in delivering the RELIEVE IBS-D virtual trial. Irritable bowel syndrome is common and causes much suffering, but its treatment is limited. We were determined to try this new treatment, and despite the challenges, we were able to do so because of three key factors: strong collaboration, a willingness to innovate, and an interest in listening to our patients."
Asada's PharmaField Innovation, with a 21-year track record, is one of the most highly regarded in the pharmaceutical industry across the UK. EnteroMed, the UK distributor of ENTEROSGEL®, specializes in the design and execution of clinical trials for medical devices. The nomination at the Pf Awards is in recognition of their successful project in a year marked by the metalloid pandemic.